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1. EPIDEMIOlOGy OF CERVICAl CANCER
Cervical cancer accounts for 8.8% of all cancers in women worldwide, making it the third most 
common malignancy in women and the seventh overall1. With an estimated 530,000 new cases 
and 275,000 deaths in 2008, it is an important public health problem1. Overall, the mortality 
to incidence ratio of cervical cancer is 52%. However, the disease has a very uneven global 
distribution; over 85% of cases are found in low resource countries, with incidence and death 
rates being the highest in sub-Saharan Africa (age-standardised rates (ASR) > 30 per 100.000), 
Central America (ASR: 23.9 per 100.000), South-Central Asia (ASR: 24.6 per 100.000) and 
Melanesia (ASR 23.9: per 100.000 (Figure 1)1-4. This imbalance in disease burden can be explained 
by differences in background risk and the fact that cervical cancer is preventable by an effective 
screening and intervention system. Therefore, the lowest incidence and mortality rates are 
recorded in countries where screening is available to women, such as in the Netherlands. 
In the Netherlands (16.8 million residents), approximately 2% of all newly diagnosed 
malignancies in women are cervical cancers, corresponding to about 700 new cases per year 
(age standardised incidence rate 6.0/100.000)5;6. Furthermore, every year about 200 women die 
from the disease (age-standardised mortality rate of 1.3/100.000), which is about 1.5% of all 
deaths in Dutch women caused by cancer 5;6.
2. HRHPV AND CERVICAl CARCINOGENESIS
2.1 Precursor lesions
Cervical cancer originates in the uterine cervix, which constitutes the lower part of the uterus 
that partly protrudes in the vagina (Figure 2). The cervix consists of two parts: the endocervix 
(the inside of the cervical canal) and the ectocervix (outer part of the cervix). The endocervix is 
lined by a single layer of glandular columnar epithelial cells, while the ectocervix and vagina are 
covered with squamous epithelium and is multi-layered. The border between these two types 
of epithelium is called the squamo-columnar junction (SCJ). From puberty onwards, vaginal PH 
acidification induces the replacement of a portion of endocervical columnar epithelium by a 
metaplastic squamous epithelium. The area between the original and the new SCJ is called the 
transformation zone (TZ). Until recently, the TZ was thought to be most susceptible to oncogenic 
influences, such as a transforming  infection with high-risk types of the human papillomavirus 
(hrHPV).  However, recent findings suggest that a small, discrete population of single layered, 
cuboidal epithelial cells of embryonic origin that localizes at the SCJ of the cervix, represents the 
likely cellular precursor of most cervical cancers and their precursor lesions7. 
Squamous cell carcinoma (SSC) is the most common histotype of cervical cancer (80%). The 
second most common type is adenocarcinoma (AdCa), accounting for approximately 15% of 
cervical cancers. The remaining 5% include rare types, such as neuro-endocrine carcinomas and 
clear-cell carcinomas.
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Cervical SSCs develop through well-characterised stages of premalignant lesions, so called 
cervical intraepithelial neoplasia (CIN), graded from 1 to 3 (CIN1, CIN2 and CIN3) 8. In case of CIN1 
(mild dysplasia) the lower 1/3 of the total thickness of the squamous epithelium shows atypia, 
in CIN2 (moderate dysplasia) the lower 2/3 of the epithelium is involved, and in CIN3 (severe 
dysplasia and carcinoma in situ) from 2/3 up to the whole epithelial layer consists of atypical 
cells. Different grades of dysplasia may coexist within the same cervix. 
Accurate grading of CIN lesions is important for clinical management of patients, because CIN1 
and CIN2/3 lesions are managed differently (i.e. surveillance versus radical treatment). Also, the 
outcome of cervical screening trials is dependent on accurate CIN lesion grading. However, 
histopathological diagnosis of CIN is complicated by a variety of cellular changes associated 
with inflammation, pregnancy and/or atrophy. These changes may mimic precancerous cervical 
lesions, thereby making cervical histology, that is, the diagnostic interpretation of H&e-stained 
slides, subjective and prone to variability 9. This is reflected in poor inter-observer agreement 
between pathologists 10-12. In particular, the differential diagnosis between immature squamous 
metaplasia and CIN1/2, or between low-grade (CIN1) and high-grade (CIN2/3) lesions, may be 
difficult 10;13;14. To overcome these problems, doubtful lesions are usually judged by more than 
one pathologist, and in case of clinical trials the diagnosis of CIN lesions is often reviewed 
by expert pathologists. Collectively, this emphasizes the need for specific biomarkers to aid 
objective CIN lesion grading, and to identify true high-grade dysplasia of the cervix 15. 
Illustration: CDC image
Figure 2. Anatomy of the uterus and cervix with transformation zone 
 
2.2 Human papillomavirus
Mucosal human papillomaviruses (HPVs) comprise a common sexually transmitted virus family 
and the majority of both men and women are infected with such viruses shortly after starting 
sexual intercourse16;17. Papillomaviruses are small, double-stranded DNA viruses. To date there 
are over 170 different types of HPV identified, of which about 40 types are known to infect the 
genital mucosa18. It is assumed that the life-time risk of acquiring a genital HPV infection is at 
least 80% 19. 
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Since the 19th century it has already been recognised that cervical cancer is associated with 
sexual activity 20, however, it was not until the 1970s that the role of HPV in the development 
of cervical carcinoma was discovered by Harald zur Hausen and colleagues 21. Since then, many 
studies have confirmed that persistent infection with a high-risk HPV (hrHPV) type is a necessary 
condition to develop cervical cancer and its premalignant lesions 22-25. hrHPV can be detected 
in almost all cervical SSCs 22, and in 94 to 100% of all AdCas 26-28. Low-risk (lr) HPV types such as 
HPV6 and HPV11 are associated with benign wart-like lesions. Based on epidemiological criteria 
at least a dozen hrHPV types have been identified (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and 
59) 24;26;29, and six types are considered as probably high-risk (26, 53, 66, 68, 73 and 82) 30. Not 
all hrHPV types confer the same risk of high-grade cervical lesions. HPV16 causes more than 
half of the cervical cancers worldwide, followed by HPV18 (approximately 16%), and HPV33 
(approximately 4%) 31. hrHPV does not only play a causal role in the development of cervical 
cancer, but also in cancers of other parts of the anogenital tract, such as anal, vulvar, and penile 
cancer, as well as of the head and neck, particularly oropharyngeal cancer 30;32-35. 
The HPV prevalence depends on geographic area, as discussed above, and age. Among women 
it is highest between the age of 20 and 25 years (approximately 20%) 17;36;37. The prevalence 
gradually declines by increasing age to under 3% in women over 45 years of age 38. Risk factors 
that are associated with acquiring an infection are the number of sexual partners, the age of 
sexarche, and smoking 25;39;40. Fortunately, at least 80% of all hrHPV infections are transient, and 
will not result in premalignant lesions or cervical cancer. Most women clear the infection within 
1-2 years after exposure 25;41. In the remaining 20% the hrHPV infection persists, which is the 
first step towards the development of a premalignant lesion. However, additional (epi)genetic 
transforming events are necessary for malignant progression25;42. Thus, genital infections are 
very common, but only a few HPV-infected individuals (approximately 1-3%) ultimately show 
progression to invasive cancer 43. 
2.3 HPV-mediated cervical carcinogenesis
HPV infections have a tight connection to the differentiation process of the infected epithelium. 
Besides the viral proteins e1 and e2, which are essential for viral replication, the virus relies 
entirely on the host cell DNA replication machinery to generate progeny. A productive HPV 
infection starts following entry of the virus into the basal cells of the cervical epithelium, 
and the virus replicates as these cells differentiate to produce the protective barrier normally 
provided by superficial epithelial cells. Viral e6 and e7 proteins are needed to allow vegative 
viral replication in differentiated, non-dividing epithelial host cells, in which the DNA replication 
machinery is normally not activated. The e7 protein binds to the retinoblastoma tumor 
suppressor protein (pRB) and disrupts the binding of pRB to e2F, which leads to S-phase entry 
through released e2F 44;45. e6 binds to the human tumor suppressor protein p53 and degrades 
this protein, which is important to prevent  cell-cycle blockade and apoptosis. When these cells 
disintegrate, as a consequence of their natural turnover at the superficial layers, new formed, 
infectious viral particles are released into the environment 42;46. Thus, the e6 and e7 proteins are 




cycle, where their regulation is tightly controlled. This productive infection may give rise to mild 
or moderate cellular abnormalities, histologically comparable with CIN1/2, but not often to true 
pre-malignant cervical lesions. 
Alternatively, a so-called persistent transforming HPV infection may arise, under conditions that 
the viral e6 and e7 proteins are improperly expressed in the proliferating basal cells, stimulating 
viral transformation 47;48. These transforming infections are associated with CIN2, CIN3 and 
cervical cancer. The mechanism underlying the deregulated expression of e6 and e7 is not fully 
understood. A possible explanation is integration of viral DNA in the host cell genome 49;50, but 
methylation of e2 binding sites has also been suggested 51. The constant over-expression of viral 
proteins e6 and e7 will result in chromosomal instability and provides the driving force to further 
progression towards cancer. The process is as follows: free e2F resulting from the interaction of 
e7 with pRB stimulates uncontrolled cell growth in proliferating cells 52. Subsequently, the cell 
cannot cope with the uncontrolled growth, due to degradation of tumor suppressor protein p53 
by e6, which triggers the development of genetic instability 53. In addition, as a consequence of 
deregulated expression of e7, the tumor suppressor protein p16INK4a  is up-regulated. p16INK4a is a 
cyclin dependent kinase inhibitor that normally prevents inactivation of pRB by cyclin D1 and 
therefore induces cell cycle arrest at G1. However, in the presence of hrHPV e7 the pRB protein 
is already inactivated, and thus upregulated p16INK4a has no effect. Yet, the overexpression of 
p16INK4a throughout the cervical epithelium can be considered as a marker for lesions that 
harbour a transforming hrHPV infection 54-56. 
In conclusion, cervical cancer develops through the following steps: hrHPV infection, hrHPV 
persistence, hrHPV transformation and development of premalignant lesions, and finally 
progression to invasive cervical cancer (Figure 3) 25.  Although the process between first hrHPV 
infection and evidence of a premalignant lesion usually requires many years, time can be as 
short as 2 to 3 years 36;42;57. Furthermore, only 1-3% of all hrHPV positive women will develop a 
transforming infection 26, which could ultimately result in invasive cancer 42;58. Next to persistence 
of a transforming infection, accumulation of additive (epi)genetic alterations is necessary for 
further progression towards invasive cancer. This final step takes on average 15-20 years 42;59. As 
mentioned earlier, a discrete population of embryonic epithelial cells represent the likely cellular 
precursor of most cervical cancers and their precursor lesions 7. Apparently, these cells, which 
are characterized by a specific immunostaining pattern, are highly susceptible to transformation 
by hrHPV. Conversely, productive infections are supposed to arise exclusively from infection of 
basal cells of the squamous epithelium lining the ectocervix or adjacent transformation zone 60. 
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Figure 3. Progression model of cervical cancer [Adapted from: Snijders et al. 2006] 42 .
3. PREVENTION OF CERVICAl CANCER
Primary prevention seeks to prevent,  by interventions, the onset of specific diseases via risk 
reduction, thus prevention of disease in healthy people. This can be achieved by altering 
behaviours or exposures that can lead to disease, or by enhancing resistance to the effects 
of exposure to a disease agent. In cervical cancer prevention, prophylactic vaccination with 
HPV16/18 L1 virus-like particles (VLPs) is an example of primary cancer prevention. VLPs 
resemble the actual virus morphologically but cannot induce infection, as these do not contain 
virus DNA.
Secondary prevention comprises procedures that detect and treat pre-clinical non-symptomatic 
pathological changes and thereby control disease progression. Cervical cancer screening by 
detection of abnormal cells in a cervical smear sample (Pap smear) is an example of secondary 
cancer prevention. 
3.1 Primary cervical cancer prevention
In the Netherlands, two prophylactic vaccines are available since 2009. A bivalent HPV16/18 
L1 VLP vaccine that protects against HPV16 and HPV18 (Cervarix®, GSK), and a quadrivalent 
vaccine that also contains VLPs of non-oncogenic types HPV6 and HPV11 (Gardasil®, MSD) 61-66. 
These vaccines provide protection against persistent infection of epithelial cells with HPV types 
represented in the vaccine, and against incident and persistent CIN2 or worse (CIN2+) lesions 
caused by the vaccine HPV types. In principle the protection is type-specific, but cross-reactivity 
against HPV45, and partially against HPV31 has been proven 28. At present, however, vaccination 




which together cause about 77% of cervical cancer cases (i.e., 70% by HPV16/18, 7% by cross-
protection) 28;67. In addition, the vaccine uptake remains suboptimal in the Netherlands, where 
HPV vaccination is offered to HPV-negative (naïve) 12-year-old girls, and an average of 56% 
coverage is observed 68. Consequently, secondary cancer prevention, i.e., screening, will remain 
the most important preventive strategy at least for the next two decades. 
3.2 Secondary cervical cancer prevention
The fact that cervical cancer develops through different premalignant stages (precursor 
lesions) which can be detected years before cervical cancer appears 25;42, offers possibilities 
for screening and treatment. This recognition has resulted in the organisation of population-
based screening programs. The benefit of such a screening program depends on the level of 
participation of invited women, the clinical sensitivity of the screening test, availability of an 
adequate intervention, and adequate follow-up protocol for women with an abnormal test 
result 25. Clinical sensitivity is the probability that a test correctly identifies people with clinically 
meaningful disease at a preclinical stage as positive. 
However, there are also negative effects of screening, such as distress due to a false  positive 
screening test, and the risk of unnecessary treatment and possible adverse effects of surgical 
treatment.
3.2.1 Current cervical cancer screening
The cytological smear, also known as Pap smear, is based on cytomorphological examination 
of exfoliated cells from the transformation zone, cells from the ectocervix and cells from the 
endocervical epithelium 69. The Pap smear is named after Dr. Papanicolaou who was the first to 
demonstrate that (precursor lesions of ) cervical cancer could be detected by this method 70. This 
finding resulted in the worldwide implementation of cytology-based screening as a diagnostic 
tool to identify cervical disease. 
In the Netherlands, cervical cancer screening using the Pap smear was introduced in the 
beginning of 1970s for women between the age of 35-55 years, with a smear taken every 3 years. 
In 1996, the screening program was revised and changed into a program with a 5-year interval 
for women aged 30-60 years 71. The main goal was to increase the effectiveness and to decrease 
the number of opportunistic smears taken outside the screening program. Another important 
change in the restructuring was implementation of a new follow-up algorithm combined with 
a more consistent classification of the cytological smear result (CISOe-A classification) 71;72. This 
resulted in a decrease in the number of equivocal diagnoses from 11.3% in 1990 to 2.6% in 
2000 (p < 0.001) 73. The CISOe-A classification (in Dutch KOPAC-B) can be converted into the 
(internationally used) Bethesda system (Table 1) 73;74. The new follow-up algorithm implied that, 
in case of borderline or mild dyskaryosis (BMD), women were recalled for repeat cytology testing 
after 6 and 18 months and were referred for colposcopy if the repeat test result was positive 
(BMD or worse) at either of these occasions. This policy is used because only 5-15% of women 
with BMD has or will develop high-grade precursor lesions 75-77. 
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In the present day, approximately 800,000 women are invited annually for cervical screening 
in the Netherlands 78. On average, 65% of the invited population participates in screening, and 
another 12% are screened on indication or have opportunistic screening. About 95% of these 
participants has a normal smear, and these women are invited for the next screening round 
in 5 years. Around 7000 women need re-testing because the sample is of inadequate quality, 
and BMD is found in approximately 2-2.5% of smears, followed by the advice to repeat testing. 
Over 3500 women are referred for colposcopy immediately because their pap smear reveals 
moderate dyskaryosis or worse 79;80. Finally, each year more than 5000 women are treated for 
a high-grade CIN lesion to prevent the development of cervical cancer, mainly through a loop 
electrosurgical excision procedure (LeeP) 81. 
Several epidemiological studies have shown that cytological screening, as implemented in the 
Netherlands, has been successful in reducing the incidence and mortality of cervical cancer 
82-85. However, cervical cancer continues to be a considerable public health problem 86;87. The 
main reasons for missing cervical cancer cases despite a screening program are a relatively low 
attendance rate (65% of invited women) and a relatively high number of false-negative cytology 
tests, due to the rather low sensitivity (50-70%) of the pap smear 88;89. Further, cytology has low 
reproducibility, leading to variable accuracy 90;91. Moreover, by repeating cytology, the number 
of false-positives increases substantially over time 92. In addition, cytology is a subjective 
test and labour intensive 93. Finally, the decrease in incidence of cervical cancer induced by 
cytology-based screening is mainly restricted to squamous cell carcinoma, whereas no change 
is observed in incidence of cervical adenocarcinoma 94-96, suggesting that cytology fails to detect 
adenocarcinomas and its precursors. Therefore, over the last decades, efforts to improve cervical 
screening have focused on increasing adherence to the screening program and on development 
of alternative (objective) screening tests that are more sensitive than cytology. 
4. IMPROVEMENT OF CERVICAl CANCER SCREENING
4.1 hrHPV-based cervical cancer screening 
The causal relationship between infection with hrHPV and cervical cancer has stimulated the 
application of hrHPV DNA testing, which has been proposed, either alone or in combination 
with cytology, as a means to improve existing cervical screening programs. In the past fifteen 
years, large randomized trials designed to evaluate the performance of hrHPV testing, have 
provided important arguments for the implementation of this assay as a primary screening tool 
97-106. 
These studies have shown that hrHPV testing detects 30% more CIN2+, and 20% more CIN3 
or worse (CIN3+) lesions in women over 30 years of age. In addition, four randomized trials 
conducted in europe, have published longitudinal data on CIN3+ diagnosed at subsequent 
screening rounds, which took place in 3 to 5 years 98;100;101;104;107. All trials reported an approximately 
50% lower CIN3+ detection rate in the second screening round among women who were hrHPV 




pooled analysis of these european trials, it was recently confirmed that hrHPV-based screening 
provides better protection against cervical cancer than cytology 108. Thus, a negative hrHPV test 
provides a better protection against high-grade precursor lesions and cervical cancer than a 
negative Pap smear, permitting less frequent screening. 
The HPV test used in these trials were the hybrid capture 2 (HC2) test and the GP5+-6+-PCR eIA 
assay, which are considered clinically validated for screening purposes 109;110. The hrHPV HC2 is 
a signal amplification method in a liquid-phase format and uses a mixture of full length RNA 
probes representing 13 HPV types (i.e., HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68) to 
hybridize to HPV DNA in heat-alkaline-denatured samples. RNA/DNA hybrids are detected by 
peroxidase-labeled antibodies and visualized by electro-chemiluminescence (eCL) 111. The GP5+-
6+-PCR eIA test is a PCR-based assay, amplifying L1 DNA of a broad-spectrum of HPV types. The 
read-out involves an enzyme immunoassay (eIA) staining procedure using oligoprobe cocktails 
representing high-risk and/or low-risk HPV types 112. However, many new hrHPV tests have been 
developed, and the clinical performance of these tests is mostly unknown. Therefore, standards 
for hrHPV test performance and characteristics in clinical practice have been formulated by an 
international consortium 109. Thus far, several additional hrHPV DNA tests, such as  Cobas 4800 
Roche®, RealTime (RT) PCR Abbott Molecular®, and Papillocheck Bio-Greiner® (when only 14 
hrHPV types are considered), have fulfilled the criteria provided in these guidelines, and can be 
considered clinically validated for primary hrHPV-based cervical cancer screening 113-119. 
Another important and consistent finding in trials with combined hrHPV and cytology co-
testing, is that co-testing has virtually no additional value compared to single hrHPV screening 
120-122. 
Collectively, the available evidence indicates that sole hrHPV testing should replace cytology 
as a primary screening tool in cervical screening. Therefore, the Dutch Minister of health has 
recently decided to use primary hrHPV screening to improve cervical screening efficacy. This will 
be implemented in the Netherlands in 2016 and comprises primary hrHPV testing in 5 screening 
rounds, at the ages of 30, 35, 40, 50 and 60 years 123.
4.2 Triage of hrHPV positive women
The drawback of primary hrHPV testing is that it has an (apparently) unavoidable trade-off 
between sensitivity and specificity. Overall, hrHPV testing has a 3-4% lower specificity for 
high-grade CIN than cytology 122; the hrHPV test detects a substantial number of women with 
transient hrHPV infections that will not  lead to clinically meaningful lesions 124;125. This may lead 
to unnecessary referral for colposcopy and possible over-treatment 103. As a result, triage testing 
of hrHPV positive women is necessary to keep the number of invasive follow-up examinations, 
and associated costs within acceptable limits 126.
epidemiological studies have indicated that detection of HPV16, HPV18, or both might be used 
to identify women with an increased risk for CIN3+ 107;121;127. Yet, in a recent hrHPV screening trial 
126, direct triage with cytology and repeat cytology testing at 12 months emerged as a suitable 
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implementation strategy. Thus, there is no consensus on the best way to manage hrHPV DNA 
positive women. In addition, in future screening, it is likely that the role of cytology becomes 
more limited and validated (molecular) biomarkers gain attention; among these, p16INK4a/Ki-67 
dual staining and host genome or viral DNA methylation markers appear to be promising 128-132.
4.3 Increasing screening coverage
One other problem concerning the effectiveness of current cervical screening programs remains 
non-attendance 133-136. Non-participating women are at increased risk of cancer 82;137, as half of the 
cervical carcinomas are found in these women. Therefore, targeting non-attendees is important 
in achieving optimal protection from screening programs. Self-sampling is a less costly and less 
invasive collection method 138, and several studies have shown that non-attendees actually do 
take part in self-sampling studies 133-135;139-143. Moreover, the detection of high-grade lesions in 
non-attendees participating in self-sampling was higher than in regular screening attendees 
134;142;144. Studies using interview surveys have shown that women prefer self-collection over 
physician-collection 138;145;146. Thus, there is a basis for self-sampling in cervical cancer screening. 
In addition, self-collection makes cervical screening accessible to women in medium- and low 
income countries 136;147;148. That is why in recent years several studies have focused on the use of 
self-collected samples for hrHPV testing. Studies have shown that hrHPV testing on self-samples 
can be non-inferior to that of physician-collected cervical samples for the detection of CIN2+, 
although reported data are rather inconsistent 138;140;149-151. This most likely reflects the use of 
different self-collection devices in combination with different HPV tests 151;152. Therefore, it is 
important that a self-collection device is clinically validated in combination with a hrHPV test, 
prior to its use as a hrHPV self-sampling procedure to re-attract non-attendees in population-
based screening, or even for primary hrHPV-based cervical screening.
5. AIM AND OUTlINE OF THIS THESIS 
Cervical cancer is induced by a persistent infection with hrHPV. This causal link has been proven 
indisputably, and strong evidence now supports the use of hrHPV testing in the prevention of 
cervical cancer. The aim of this thesis was to evaluate the clinical accuracy of hrHPV selfsampling, 
the value of different triage strategies and biomarker-guided CIN grading. More specifically, the 
studies described in this thesis aimed to answer the following questions:
•	 Is brush-based self-sampling in combination with GP5+/6+-PCR eIA hrHPV testing valid 
for assessing CIN2+ risk, in comparison to hrHPV testing on physician-taken scrapes? And 
what is the compatibility between self- and physician-collected samples at the level of 
HPV genotyping? (Chapter 2: Brush-based self-sampling in combination with GP5+/6+-
PCR-based hrHPV testing: High concordance with physician-taken cervical scrapes for HPV 




•	 Does replacing the first generation self-sampling lavage device by an ergonomically 
improved, second generation device result in higher response rates among non-responders 
of the Dutch cervical screening program? And is the clinical performance of both models 
comparable? (Chapter 3: A second generation cervico-vaginal lavage device shows similar 
performance as its preceding version with respect to DNA yield and HPV DNA results)
•	 What are implementable triage strategies for primary hrHPV screening in an organized 
setting? (Chapter 4: Primary hrHPV DNA testing in cervical cancer screening: how to manage 
screen positive women? A POBASCAM Trial sub study)
•	 What are benefits of hrHPV-based screening compared to cytology-based screening. And 
what is the duration of the protection provided by a negative triage test for future CIN3 and 
cancer, for several strategies to triage hrHPV positive women.(Chapter 5: CIN3 and cancer 
risks after primary HPV DNA testing and cytology triage in cervical cancer screening: fifteen 
years follow-up of a randomized controlled trial)
•	 Does the use of p16INK4a immunohistochemistry improve the accuracy of grading CIN lesions? 
(Chapter 6: p16INK4a immunostaining as an alternative to histology review for reliable grading 
of cervical intraepithelial lesions)
•	 In Chapter 7, we provide an overview of the arguments in favour of, and concerns on aspects 
of implementation of hrHPV testing in primary cervical cancer screening (discussion). This 
thesis ends with a summary of the findings, and future prospects in Chapter 8.
CerviCal CanCer sCreening 2.022
REFERENCE lIST
1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, 
Parkin DM. estimates of worldwide burden of 
cancer in 2008: GLOBOCAN 2008. Int J Cancer 
2010; 127(12):2893-2917.
2. Arbyn M, Castellsague X, de SS, Bruni L, Saraiya 
M, Bray F et al. Worldwide burden of cervical 
cancer in 2008. Ann Oncol 2011; 22(12):2675-
2686.
3. IARC. WHO/ICO Information Centre on HPV 
and Cervical Cancer (HPV Information Centre). 
Human Papillomavirus and Related Cancers in 
World. 2010.  2010. Ref Type: Report
4. Forman D, de MC, Lacey CJ, Soerjomataram I, 
Lortet-Tieulent J, Bruni L et al. Global burden 
of human papillomavirus and related diseases. 
Vaccine 2012; 30 Suppl 5:F12-F23.
5. Nederland IKC 2011. Cijfers over kanker. 
available from http://www.cijfersoverkanker.nl. 
2011. Ref Type: Online Source
6. Centraal bureau voor de statistiek. available 
from: http//:www.cbs.nl.  2013. Ref Type: Online 
Source
7. Herfs M, Yamamoto Y, Laury A, Wang X, Nucci 
MR, McLaughlin-Drubin Me et al. A discrete 
population of squamocolumnar junction 
cells implicated in the pathogenesis of 
cervical cancer. Proc Natl Acad Sci U S A 2012; 
109(26):10516-10521.
8. McCredie MR, Sharples KJ, Paul C, Baranyai J, 
Medley G, Jones RW et al. Natural history of 
cervical neoplasia and risk of invasive cancer in 
women with cervical intraepithelial neoplasia 3: 
a retrospective cohort study. Lancet Oncol 2008; 
9(5):425-434.
9. Zhang Q, Kuhn L, Denny LA, De Souza M, Taylor 
S, Wright TC, Jr. Impact of utilizing p16INK4A 
immunohistochemistry on estimated 
performance of three cervical cancer screening 
tests. Int J Cancer 2007; 120(2):351-356.
10. de Vet HC, Knipschild PG, Schouten HJ, 
Koudstaal J, Kwee WS, Willebrand D et al. 
Interobserver variation in histopathological 
grading of cervical dysplasia. J Clin Epidemiol 
1990; 43(12):1395-1398.
 
11. Stoler MH, Schiffman M. Interobserver 
reproducibility of cervical cytologic and 
histologic interpretations: realistic estimates 
from the ASCUS-LSIL Triage Study. JAMA 2001; 
285(11):1500-1505.
12. O’Neill CJ, McCluggage WG. p16 expression 
in the female genital tract and its value in 
diagnosis. Adv Anat Pathol 2006; 13(1):8-15.
13. de Vet HC, Knipschild PG, Schouten HJ, 
Koudstaal J, Kwee WS, Willebrand D et al. Sources 
of interobserver variation in histopathological 
grading of cervical dysplasia. J Clin Epidemiol 
1992; 45(7):785-790.
14. Grenko RT, Abendroth CS, Frauenhoffer 
ee, Ruggiero FM, Zaino RJ. Variance in the 
interpretation of cervical biopsy specimens 
obtained for atypical squamous cells of 
undetermined significance. Am J Clin Pathol 
2000; 114(5):735-740.
15. Murphy N, Ring M, Killalea AG, Uhlmann V, 
O’Donovan M, Mulcahy F et al. p16INK4A as a 
marker for cervical dyskaryosis: CIN and cGIN 
in cervical biopsies and ThinPrep smears. J Clin 
Pathol 2003; 56(1):56-63.
16. Baseman JG, Koutsky LA. The epidemiology of 
human papillomavirus infections. J Clin Virol 
2005; 32 Suppl 1:S16-S24.
17. Collins S, Mazloomzadeh S, Winter H, Blomfield 
P, Bailey A, Young LS et al. High incidence of 
cervical human papillomavirus infection in 
women during their first sexual relationship. 
BJOG 2002; 109(1):96-98.
18. de Villiers eM. Cross-roads in the classification of 
papillomaviruses. Virology 2013; 445(1-2):2-10.
19. Syrjanen K, Hakama M, Saarikoski S, Vayrynen 
M, Yliskoski M, Syrjanen S et al. Prevalence, 
incidence, and estimated life-time risk of 
cervical human papillomavirus infections in 
a nonselected Finnish female population. Sex 
Transm Dis 1990; 17(1):15-19.
20. Statistical facts about cancers on which 
Doctor Rigoni-Stern based his contribution to 
the Surgeon’subgroup of the IV Congress of 
the Italian Scientists on 23 September 1842. 




21. zur HH, Gissmann L, Steiner W, Dippold W, 
Dreger I. Human papilloma viruses and cancer. 
Bibl Haematol 1975;(43):569-571.
22. Walboomers JM, Jacobs MV, Manos MM, 
Bosch FX, Kummer JA, Shah KV et al. Human 
papillomavirus is a necessary cause of invasive 
cervical cancer worldwide. J Pathol 1999; 
189(1):12-19.
23. Bosch FX, Manos MM, Munoz N, Sherman M, 
Jansen AM, Peto J et al. Prevalence of human 
papillomavirus in cervical cancer: a worldwide 
perspective. International biological study 
on cervical cancer (IBSCC) Study Group. J Natl 
Cancer Inst 1995; 87(11):796-802.
24. Munoz N, Bosch FX, de Sanjose S, Herrero R, 
Castellsague X, Shah KV et al. epidemiologic 
classification of human papillomavirus types 
associated with cervical cancer. N Engl J Med 
2003; 348(6):518-527.
25. Schiffman M, Castle Pe, Jeronimo J, Rodriguez 
AC, Wacholder S. Human papillomavirus and 
cervical cancer. Lancet 2007; 370(9590):890-907.
26. Bosch FX, Lorincz A, Munoz N, Meijer CJ, 
Shah KV. The causal relation between human 
papillomavirus and cervical cancer. J Clin Pathol 
2002; 55(4):244-265.
27. Zielinski GD, Rozendaal L, Voorhorst FJ, Berkhof 
J, Snijders PJ, Risse eJ et al. HPV testing can 
reduce the number of follow-up visits in women 
treated for cervical intraepithelial neoplasia 
grade 3. Gynecol Oncol 2003; 91(1):67-73.
28. de SS, Quint WG, Alemany L, Geraets DT, 
Klaustermeier Je, Lloveras B et al. Human 
papillomavirus genotype attribution in 
invasive cervical cancer: a retrospective cross-
sectional worldwide study. Lancet Oncol 2010; 
11(11):1048-1056.
29. Cogliano V, Baan R, Straif K, Grosse Y, Secretan 
B, el Ghissassi F. Carcinogenicity of human 
papillomaviruses. Lancet Oncol 2005; 6(4):204.
30. Munoz N, Castellsague X, de Gonzalez AB, 
Gissmann L. Chapter 1: HPV in the etiology of 
human cancer. Vaccine 2006; 24 Suppl 3:S3-
1-S310.
31. Clifford G, Franceschi S, Diaz M, Munoz N, Villa 
LL. Chapter 3: HPV type-distribution in women 
with and without cervical neoplastic diseases. 
Vaccine 2006; 24 Suppl 3:S26-S34.
32. Daling JR, Madeleine MM, Johnson LG, 
Schwartz SM, Shera KA, Wurscher MA et al. 
Human papillomavirus, smoking, and sexual 
practices in the etiology of anal cancer. Cancer 
2004; 101(2):270-280.
33. Heideman DA, Waterboer T, Pawlita M, 
Delis-van DP, Nindl I, Leijte JA et al. Human 
papillomavirus-16 is the predominant type 
etiologically involved in penile squamous cell 
carcinoma. J Clin Oncol 2007; 25(29):4550-4556.
34. Braakhuis BJ, Brakenhoff RH, Meijer CJ, Snijders 
PJ, Leemans CR. Human papilloma virus in head 
and neck cancer: the need for a standardised 
assay to assess the full clinical importance. Eur 
J Cancer 2009; 45(17):2935-2939.
35. Parkin DM, Bray F. Chapter 2: The burden of 
HPV-related cancers. Vaccine 2006; 24 Suppl 
3:S3-11-S3/25.
36. Woodman CB, Collins S, Winter H, Bailey A, ellis 
J, Prior P et al. Natural history of cervical human 
papillomavirus infection in young women: 
a longitudinal cohort study. Lancet 2001; 
357(9271):1831-1836.
37. Burchell AN, Richardson H, Mahmud SM, Trottier 
H, Tellier PP, Hanley J et al. Modeling the Sexual 
Transmissibility of Human Papillomavirus 
Infection using Stochastic Computer Simulation 
and empirical Data from a Cohort Study of 
Young Women in Montreal, Canada. Am J 
Epidemiol 2006; 163(6):534-543.
38. Coupe VM, Berkhof J, Bulkmans NW, Snijders 
PJ, Meijer CJ. Age-dependent prevalence of 
14 high-risk HPV types in the Netherlands: 
implications for prophylactic vaccination and 
screening. Br J Cancer 2008; 98(3):646-651.
39. Ho GY, Bierman R, Beardsley L, Chang CJ, 
Burk RD. Natural history of cervicovaginal 
papillomavirus infection in young women. N 
Engl J Med 1998; 338(7):423-428.
40. Appleby P, Beral V, Berrington de GA, Colin D, 
Franceschi S, Goodill A et al. Carcinoma of the 
cervix and tobacco smoking: collaborative 
reanalysis of individual data on 13,541 women 
with carcinoma of the cervix and 23,017 
women without carcinoma of the cervix from 
23 epidemiological studies. Int J Cancer 2006; 
118(6):1481-1495.
CerviCal CanCer sCreening 2.024
41. Bulkmans NW, Berkhof J, Bulk S, Bleeker MC, 
van Kemenade FJ, Rozendaal L et al. High-risk 
HPV type-specific clearance rates in cervical 
screening. Br J Cancer 2007; 96(9):1419-1424.
42. Snijders PJ, Steenbergen RD, Heideman 
DA, Meijer CJ. HPV-mediated cervical 
carcinogenesis: concepts and clinical 
implications. J Pathol 2006; 208(2):152-164.
43. Schiffman MH. Recent progress in defining 
the epidemiology of human papillomavirus 
infection and cervical neoplasia. J Natl Cancer 
Inst 1992; 84(6):394-398.
44. Doorbar J. Papillomavirus life cycle organization 
and biomarker selection. Dis Markers 2007; 
23(4):297-313.
45. von Knebel DM. New markers for cervical 
dysplasia to visualise the genomic chaos 
created by aberrant oncogenic papillomavirus 
infections. Eur J Cancer 2002; 38(17):2229-2242.
46. Stanley M. Immune responses to human 
papillomavirus. Vaccine 2005.
47. Scheffner M, Romanczuk H, Munger K, 
Huibregtse JM, Mietz JA, Howley PM. Functions 
of human papillomavirus proteins. Curr Top 
Microbiol Immunol 1994; 186:83-99.
48. Arbeit JM, Munger K, Howley PM, Hanahan D. 
Progressive squamous epithelial neoplasia in 
K14-human papillomavirus type 16 transgenic 
mice. J Virol 1994; 68(7):4358-4368.
49. Duensing S, Munger K. Centrosome 
abnormalities, genomic instability and 
carcinogenic progression. Biochim Biophys Acta 
2001; 1471(2):M81-M88.
50. Wentzensen N, Vinokurova S, von Knebel DM. 
Systematic review of genomic integration 
sites of human papillomavirus genomes in 
epithelial dysplasia and invasive cancer of the 
female lower genital tract. Cancer Res 2004; 
64(11):3878-3884.
51. Bhattacharjee B, Sengupta S. CpG methylation 
of HPV 16 LCR at e2 binding site proximal to P97 
is associated with cervical cancer in presence of 
intact e2. Virology 2006; 354(2):280-285.
52. Munger K, Werness BA, Dyson N, Phelps WC, 
Harlow e, Howley PM. Complex formation 
of human papillomavirus e7 proteins with 
the retinoblastoma tumor suppressor gene 
product. EMBO J 1989; 8(13):4099-4105.
53. Werness BA, Levine AJ, Howley PM. Association 
of human papillomavirus types 16 and 18 e6 
proteins with p53. Science 1990; 248(4951):76-79.
54. Lambert AP, Anschau F, Schmitt VM. p16INK4A 
expression in cervical premalignant and 
malignant lesions. Exp Mol Pathol 2006; 
80(2):192-196.
55. Queiroz C, Silva TC, Alves VA, Villa LL, Costa MC, 
Travassos AG et al. P16(INK4a) expression as a 
potential prognostic marker in cervical pre-
neoplastic and neoplastic lesions. Pathol Res 
Pract 2006; 202(2):77-83.
56. Wentzensen N, von Knebel DM. Biomarkers in 
cervical cancer screening. Dis Markers 2007; 
23(4):315-330.
57. Rodriguez AC, Schiffman M, Herrero R, 
Hildesheim A, Bratti C, Sherman Me et al. 
Longitudinal study of human papillomavirus 
persistence and cervical intraepithelial 
neoplasia grade 2/3: critical role of duration of 
infection. J Natl Cancer Inst 2010; 102(5):315-
324.
58. Ostor AG. Natural history of cervical 
intraepithelial neoplasia: a critical review. Int J 
Gynecol Pathol 1993; 12(2):186-192.
59. Vink MA, Bogaards JA, van Kemenade 
FJ, de Melker He, Meijer CJ, Berkhof J. 
Clinical progression of high-grade cervical 
intraepithelial neoplasia: estimating the time 
to preclinical cervical cancer from doubly 
censored national registry data. Am J Epidemiol 
2013; 178(7):1161-1169.
60. McNairn AJ, Guasch G. epithelial transition 
zones: merging microenvironments, niches, 
and cellular transformation. Eur J Dermatol 
2011; 21 Suppl 2:21-28.
61. Harper DM, Franco eL, Wheeler CM, Moscicki 
AB, Romanowski B, Roteli-Martins CM et al. 
Sustained efficacy up to 4.5 years of a bivalent 
L1 virus-like particle vaccine against human 
papillomavirus types 16 and 18: follow-up 





62. Paavonen J, Naud P, Salmeron J, Wheeler CM, 
Chow SN, Apter D et al. efficacy of human 
papillomavirus (HPV)-16/18 AS04-adjuvanted 
vaccine against cervical infection and precancer 
caused by oncogenic HPV types (PATRICIA): final 
analysis of a double-blind, randomised study in 
young women. Lancet 2009; 374(9686):301-314.
63. Villa LL, Costa RL, Petta CA, Andrade RP, Ault 
KA, Giuliano AR et al. Prophylactic quadrivalent 
human papillomavirus (types 6, 11, 16, and 18) 
L1 virus-like particle vaccine in young women: 
a randomised double-blind placebo-controlled 
multicentre phase II efficacy trial. Lancet Oncol 
2005; 6(5):271-278.
64. Villa LL. Prophylactic HPV vaccines: reducing 
the burden of HPV-related diseases. Vaccine 
2006; 24 Suppl 1:S23-S28.
65. Villa LL, Costa RL, Petta CA, Andrade RP, 
Paavonen J, Iversen Oe et al. High sustained 
efficacy of a prophylactic quadrivalent human 
papillomavirus types 6/11/16/18 L1 virus-like 
particle vaccine through 5 years of follow-up. Br 
J Cancer 2006; 95(11):1459-1466.
66.  (66)  Ault KA. effect of prophylactic human 
papillomavirus L1 virus-like-particle vaccine 
on risk of cervical intraepithelial neoplasia 
grade 2, grade 3, and adenocarcinoma in situ: 
a combined analysis of four randomised clinical 
trials. Lancet 2007; 369(9576):1861-1868.
67. Mesher D, Soldan K, Howell-Jones R, Panwar 
K, Manyenga P, Jit M et al. Reduction in HPV 
16/18 prevalence in sexually active young 
women following the introduction of HPV 
immunisation in england. Vaccine 2013.
68. Lier eA van. Vaccinatiegraad Rijksvaccinatie-
programma Nederland; verslagjaar 2012. 
Bilthoven. RIVM rapport 2012.  2013. Ref Type: 
Report
69. Koss LG. The Papanicolaou test for cervical 
cancer detection. A triumph and a tragedy. 
JAMA 1989; 261(5):737-743.
70. Papanicolaou GN, Traut HF. The diagnostic value 
of vaginal smears in carcinoma of the uterus. 
1941. Arch Pathol Lab Med 1997; 121(3):211-224.
71. Hanselaar AG. The population-based screening 
for cervical cancer. A uniform framework for 
cytopathological diagnosis (In Dutch). Medisch 
Contact 1995; 50(49):1590-1592.
72. Hanselaar AG. Criteria for organized cervical 
screening programs. Special emphasis on 
The Netherlands program. Acta Cytol 2002; 
46(4):619-629.
73. Bulk S, van Kemenade FJ, Rozendaal L, Meijer 
CJ. The Dutch CISOe-A framework for cytology 
reporting increases efficacy of screening upon 
standardisation since 1996. J Clin Pathol 2004; 
57(4):388-393.
74. Bulkmans NW, Rozendaal L, Snijders PJ, 
Voorhorst FJ, Boeke AJ, Zandwijken GR et al. 
POBASCAM, a population-based randomized 
controlled trial for implementation of high-
risk HPV testing in cervical screening: design, 
methods and baseline data of 44,102 women. 
Int J Cancer 2004; 110(1):94-101.
75. Cuzick J, Szarewski A, Cubie H, Hulman G, 
Kitchener H, Luesley D et al. Management of 
women who test positive for high-risk types of 
human papillomavirus: the HART study. Lancet 
2003; 362(9399):1871-1876.
76. Zielinski GD, Snijders PJ, Rozendaal L, Voorhorst 
FJ, Runsink AP, de Schipper FA et al. High-risk 
HPV testing in women with borderline and 
mild dyskaryosis: long-term follow-up data and 
clinical relevance. J Pathol 2001; 195(3):300-306.
77. Clavel C, Masure M, Bory JP, Putaud I, 
Mangeonjean C, Lorenzato M et al. Human 
papillomavirus testing in primary screening for 
the detection of high-grade cervical lesions: 
a study of 7932 women. Br J Cancer 2001; 
84(12):1616-1623.
78. Health council of the Netherlands. Health 
Council of the Netherlands. Population 
screening for cervical cancer. The Hague: Health 
Council of the Netherlands, 2011; publication 
no. 2011/07.  2011. Ref Type: Generic
79. van Ballegooijen M. Kritische kengetallen 2004-
2008: een eerste commentaar. Rotterdam. 
erasmusMC.  2009. Ref Type: Report 
80. Landelijk evaluatieteam voor bevolkingson-
derzoek naar baarmoederhalskanker. LeBA-
rapportage 2009. available from: http//
www.bevolkingsonderzoeknaarkanker.nl/
baarmoederhalskanker/evaluatie/analyse. 
2009. Ref Type: Online Source
CerviCal CanCer sCreening 2.026
81. van Ballegooijen M, Rebolj M, Meerding WJ, van 
den Akker-van Marle, Berkers LM, Habbema F. 
De praktijk van het bevolkingsonderzoek naar 
baarmoederhalskanker in Nederland in 2001. 
2003. Ref Type: Report
82. Peto J, Gilham C, Fletcher O, Matthews Fe. 
The cervical cancer epidemic that screening 
has prevented in the UK. Lancet 2004; 
364(9430):249-256.
83. Bray F, Carstensen B, Moller H, Zappa M, Zakelj 
MP, Lawrence G et al. Incidence trends of 
adenocarcinoma of the cervix in 13 european 
countries. Cancer Epidemiol Biomarkers Prev 
2005; 14(9):2191-2199.
84. Karim-Kos He, de Ve, Soerjomataram I, 
Lemmens V, Siesling S, Coebergh JW. Recent 
trends of cancer in europe: a combined 
approach of incidence, survival and mortality 
for 17 cancer sites since the 1990s. Eur J Cancer 
2008; 44(10):1345-1389.
85. Arbyn M, Raifu AO, Weiderpass e, Bray F, Anttila 
A. Trends of cervical cancer mortality in the 
member states of the european Union. Eur J 
Cancer 2009; 45(15):2640-2648.
86. van Ballegooijen M, Hermens R. Cervical cancer 
screening in the Netherlands. Eur J Cancer 2000; 
36(17):2244-2246.
87. de Kok IM, van der Aa MA, van BM, Siesling S, 
Karim-Kos He, van Kemenade FJ et al. Trends in 
cervical cancer in the Netherlands until 2007: 
has the bottom been reached? Int J Cancer 
2011; 128(9):2174-2181.
88. Bos AB, Rebolj M, Habbema JD, van Ballegooijen 
M. Nonattendance is still the main limitation 
for the effectiveness of screening for cervical 
cancer in the Netherlands. Int J Cancer 2006; 
119(10):2372-2375.
89. Kitchener HC, Castle Pe, Cox JT. Chapter 7: 
Achievements and limitations of cervical 
cytology screening. Vaccine 2006; 24 Suppl 
3:S3-63-S3/70.
90. Nanda K, McCrory DC, Myers eR, Bastian LA, 
Hasselblad V, Hickey JD et al. Accuracy of the 
Papanicolaou test in screening for and follow-up 
of cervical cytologic abnormalities: a systematic 
review. Ann Intern Med 2000; 132(10):810-819.
91. Fahey MT, Irwig L, Macaskill P. Meta-analysis 
of Pap test accuracy. Am J Epidemiol 1995; 
141(7):680-689.
92. Katki HA, Wentzensen N. How might HPV 
testing be integrated into cervical screening? 
Lancet Oncol 2012; 13(1):8-10.
93. Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, 
Ronco G, Mayrand MH et al. Overview of human 
papillomavirus-based and other novel options 
for cervical cancer screening in developed and 
developing countries. Vaccine 2008; 26 Suppl 
10:K29-K41.
94. Bulk S, Visser O, Rozendaal L, Verheijen RH, Meijer 
CJ. Cervical cancer in the Netherlands 1989-1998: 
Decrease of squamous cell carcinoma in older 
women, increase of adenocarcinoma in younger 
women. Int J Cancer 2005; 113(6):1005-1009.
95. Bergstrom R, Sparen P, Adami HO. Trends in 
cancer of the cervix uteri in Sweden following 
cytological screening. Br J Cancer 1999; 
81(1):159-166.
96. Anttila A, Pukkala e, Soderman B, Kallio M, 
Nieminen P, Hakama M. effect of organised 
screening on cervical cancer incidence and 
mortality in Finland, 1963-1995: recent increase 
in cervical cancer incidence. Int J Cancer 1999; 
83(1):59-65.
97. Mayrand MH, Duarte-Franco e, Rodrigues I, 
Walter SD, Hanley J, Ferenczy A et al. Human 
papillomavirus DNA versus Papanicolaou 
screening tests for cervical cancer. N Engl J Med 
2007; 357(16):1579-1588.
98. Rijkaart DC, Berkhof J, Rozendaal L, van 
Kemenade FJ, Bulkmans NW, Heideman DA et al. 
Human papillomavirus testing for the detection 
of high-grade cervical intraepithelial neoplasia 
and cancer: final results of the POBASCAM 
randomised controlled trial. Lancet Oncol 2012; 
13(1):78-88.
99. Kitchener HC, Almonte M, Wheeler P, Desai M, 
Gilham C, Bailey A et al. HPV testing in routine 
cervical screening: cross sectional data from the 
ARTISTIC trial. Br J Cancer 2006; 95(1):56-61.
100. Kitchener HC, Almonte M, Thomson C, Wheeler 
P, Sargent A, Stoykova B et al. HPV testing 
in combination with liquid-based cytology 
in primary cervical screening (ARTISTIC): a 
randomised controlled trial. Lancet Oncol 2009; 
10(7):672-682.
101. Naucler P, Ryd W, Tornberg S, Strand A, Wadell 
G, elfgren K et al. Human papillomavirus and 
Papanicolaou tests to screen for cervical cancer. 




102. Ronco G, Segnan N, Giorgi-Rossi P, Zappa M, 
Casadei GP, Carozzi F et al. Human papillomavirus 
testing and liquid-based cytology: results at 
recruitment from the new technologies for 
cervical cancer randomized controlled trial. J 
Natl Cancer Inst 2006; 98(11):765-774.
103. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, 
Dalla PP, Del MA et al. Results at recruitment 
from a randomized controlled trial comparing 
human papillomavirus testing alone with 
conventional cytology as the primary cervical 
cancer screening test. J Natl Cancer Inst 2008; 
100(7):492-501.
104. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini 
M, Dalla PP, Del MA et al. efficacy of human 
papillomavirus testing for the detection 
of invasive cervical cancers and cervical 
intraepithelial neoplasia: a randomised 
controlled trial. Lancet Oncol 2010; 11(3):249-
257.
105. Leinonen M, Nieminen P, Kotaniemi-Talonen L, 
Malila N, Tarkkanen J, Laurila P et al. Age-specific 
evaluation of primary human papillomavirus 
screening vs conventional cytology in a 
randomized setting. J Natl Cancer Inst 2009; 
101(23):1612-1623.
106. Sankaranarayanan R, Nene BM, Shastri SS, 
Jayant K, Muwonge R, Budukh AM et al. HPV 
screening for cervical cancer in rural India. N 
Engl J Med 2009; 360(14):1385-1394.
107. Bulkmans NW, Berkhof J, Rozendaal L, van 
Kemenade FJ, Boeke AJ, Bulk S et al. Human 
papillomavirus DNA testing for the detection 
of cervical intraepithelial neoplasia grade 3 
and cancer: 5-year follow-up of a randomised 
controlled implementation trial. Lancet 2007; 
370(9601):1764-1772.
108. Ronco G, Dillner J, elfstrom KM, Tunesi S, 
Snijders PJ, Arbyn M et al. efficacy of HPV-based 
screening for prevention of invasive cervical 
cancer: follow-up of four european randomised 
controlled trials. Lancet 2013.
109. Meijer CJ, Berkhof J, Castle Pe, Hesselink AT, 
Franco eL, Ronco G et al. Guidelines for human 
papillomavirus DNA test requirements for 
primary cervical cancer screening in women 30 
years and older. Int J Cancer 2009; 124(3):516-
520.
110. Meijer CJ, Berkhof H, Heideman DA, Hesselink 
AT, Snijders PJ. Validation of high-risk HPV tests 
for primary cervical screening. J Clin Virol 2009; 
46 Suppl 3:S1-S4.
111. Terry G, Ho L, Londesborough P, Cuzick J, 
Mielzynska-Lohnas I, Lorincz A. Detection of 
high-risk HPV types by the hybrid capture 2 test. 
J Med Virol 2001; 65(1):155-162.
112. Jacobs MV, de Roda Husman AM, van den 
Brule AJ, Snijders PJ, Meijer CJ, Walboomers JM. 
Group-specific differentiation between high- 
and low-risk human papillomavirus genotypes 
by general primer-mediated PCR and two 
cocktails of oligonucleotide probes. J Clin 
Microbiol 1995; 33(4):901-905.
113. Castle Pe, Sadorra M, Lau T, Aldrich C, Garcia 
FA, Kornegay J. evaluation of a prototype 
real-time PCR assay for carcinogenic 
human papillomavirus (HPV) detection and 
simultaneous HPV genotype 16 (HPV16) and 
HPV18 genotyping. J Clin Microbiol 2009; 
47(10):3344-3347.
114. Snijders PJ, Heideman DA, Meijer CJ. Methods 
for HPV detection in exfoliated cell and tissue 
specimens. APMIS 2010; 118(6-7):520-528.
115. Hesselink AT, Heideman DA, Berkhof J, Topal 
F, Pol RP, Meijer CJ et al. Comparison of the 
clinical performance of PapilloCheck human 
papillomavirus detection with that of the 
GP5+/6+-PCR-enzyme immunoassay in 
population-based cervical screening. J Clin 
Microbiol 2010; 48(3):797-801.
116. Heideman DA, Hesselink AT, Berkhof J, van 
KF, Melchers WJ, Daalmeijer NF et al. Clinical 
validation of the cobas 4800 HPV test for 
cervical screening purposes. J Clin Microbiol 
2011; 49(11):3983-3985.
117. Carozzi FM, Burroni e, Bisanzi S, Puliti D, 
Confortini M, Giorgi RP et al. Comparison of 
clinical performance of Abbott RealTime High 
Risk HPV test with that of hybrid capture 2 assay 
in a screening setting. J Clin Microbiol 2011; 
49(4):1446-1451.
118. Poljak M, Cuzick J, Kocjan BJ, Iftner T, Dillner J, 
Arbyn M. Nucleic acid tests for the detection of 
alpha human papillomaviruses. Vaccine 2012; 
30 Suppl 5:F100-F106.
CerviCal CanCer sCreening 2.028
119. Hesselink AT, Meijer CJ, Poljak M, Berkhof J, van 
Kemenade FJ, van der Salm ML et al. Clinical 
validation of the Abbott RealTime High Risk 
HPV assay according to the guidelines for 
human papillomavirus DNA test requirements 
for cervical screening. J Clin Microbiol 2013; 
51(7):2409-2410.
120. Arbyn M, Ronco G, Meijer CJ, Naucler P. 
Trials comparing cytology with human 
papillomavirus screening. Lancet Oncol 2009; 
10(10):935-936.
121. Katki HA, Kinney WK, Fetterman B, Lorey T, 
Poitras Ne, Cheung L et al. Cervical cancer risk 
for women undergoing concurrent testing for 
human papillomavirus and cervical cytology: 
a population-based study in routine clinical 
practice. Lancet Oncol 2011; 12(7):663-672.
122. Arbyn M, Ronco G, Anttila A, Meijer CJ, Poljak 
M, Ogilvie G et al. evidence regarding human 
papillomavirus testing in secondary prevention 
of cervical cancer. Vaccine 2012; 30 Suppl 
5:F88-F99.
123. RIVM. RIVM Report 225121002/2013; feasibility 
study for improvements to the population 
screening for cervical cancer.  2013.  2013. Ref 
Type: Report
124. Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer 
H, Ratnam S et al. Overview of the european 
and North American studies on HPV testing in 
primary cervical cancer screening. Int J Cancer 
2006; 119(5):1095-1101.
125. Arbyn M, Sasieni P, Meijer CJ, Clavel C, 
Koliopoulos G, Dillner J. Chapter 9: Clinical 
applications of HPV testing: A summary of meta-
analyses. Vaccine 2006; 24 Suppl 3:S78-S89.
126. Rijkaart DC, Berkhof J, van Kemenade FJ, Coupe 
VM, Hesselink AT, Rozendaal L et al. evaluation 
of 14 triage strategies for HPV DNA-positive 
women in population-based cervical screening. 
Int J Cancer 2012; 130(3):602-610.
127. Khan MJ, Castle Pe, Lorincz AT, Wacholder S, 
Sherman M, Scott DR et al. The elevated 10-year 
risk of cervical precancer and cancer in women 
with human papillomavirus (HPV) type 16 or 
18 and the possible utility of type-specific HPV 
testing in clinical practice. J Natl Cancer Inst 
2005; 97(14):1072-1079.
128. Carozzi F, Cecchini S, Confortini M, Becattini 
V, Cariaggi MP, Pontenani G et al. Role of 
P16(INK4a) expression in identifying CIN2 
or more severe lesions among HPV-positive 
patients referred for colposcopy after abnormal 
cytology. Cancer 2006; 108(2):119-123.
129. Overmeer RM, Henken Fe, Snijders PJ, Claassen-
Kramer D, Berkhof J, Helmerhorst TJ et al. 
Association between dense CADM1 promoter 
methylation and reduced protein expression in 
high-grade CIN and cervical SCC. J Pathol 2008; 
215(4):388-397.
130. Klaes R, Friedrich T, Spitkovsky D, Ridder R, Rudy 
W, Petry U et al. Overexpression of p16(INK4A) 
as a specific marker for dysplastic and neoplastic 
epithelial cells of the cervix uteri. Int J Cancer 
2001; 92(2):276-284.
131. Hesselink AT, Heideman DA, Steenbergen 
RD, Coupe VM, Overmeer RM, Rijkaart D et al. 
Combined promoter methylation analysis of 
CADM1 and MAL: an objective triage tool for 
high-risk human papillomavirus DNA-positive 
women. Clin Cancer Res 2011; 17(8):2459-2465.
132. Carozzi F, Confortini M, Dalla PP, Del MA, 
Gillio-Tos A, De ML et al. Use of p16-INK4A 
overexpression to increase the specificity 
of human papillomavirus testing: a nested 
substudy of the NTCC randomised controlled 
trial. Lancet Oncol 2008; 9(10):937-945.
133. Szarewski A, Cadman L, Mesher D, Austin J, 
Ashdown-Barr L, edwards R et al. HPV self-
sampling as an alternative strategy in non-
attenders for cervical screening - a randomised 
controlled trial. Br J Cancer 2011; 104(6):915-920.
134. Wikstrom I, Lindell M, Sanner K, Wilander e. 
Self-sampling and HPV testing or ordinary 
Pap-smear in women not regularly attending 
screening: a randomised study. Br J Cancer 2011; 
105(3):337-339.
135. Snijders PJ, Verhoef VM, Arbyn M, Ogilvie G, 
Minozzi S, Banzi R et al. High-risk HPV testing 
on self-sampled versus clinician-collected 
specimens: a review on the clinical accuracy 
and impact on population attendance in 
cervical cancer screening. Int J Cancer 2013; 
132(10):2223-2236.
136. Holanda F, Jr., Castelo A, Veras TM, de Almeida 
FM, Lins MZ, Dores GB. Primary screening for 
cervical cancer through self sampling. Int J 




137. Sasieni P, Adams J, Cuzick J. Benefit of cervical 
screening at different ages: evidence from the 
UK audit of screening histories. Br J Cancer 2003; 
89(1):88-93.
138. Petignat P, Faltin DL, Bruchim I, Tramer MR, 
Franco eL, Coutlee F. Are self-collected samples 
comparable to physician-collected cervical 
specimens for human papillomavirus DNA 
testing? A systematic review and meta-analysis. 
Gynecol Oncol 2007; 105(2):530-535.
139. Bais AG, van Kemenade FJ, Berkhof J, Verheijen 
RH, Snijders PJ, Voorhorst F et al. Human 
papillomavirus testing on self-sampled 
cervicovaginal brushes: an effective alternative 
to protect nonresponders in cervical screening 
programs. Int J Cancer 2007; 120(7):1505-1510.
140. Brink AA, Meijer CJ, Wiegerinck MA, Nieboer 
Te, Kruitwagen RF, van Kemenade F et al. High 
concordance of results of testing for human 
papillomavirus in cervicovaginal samples 
collected by two methods, with comparison of 
a novel self-sampling device to a conventional 
endocervical brush. J Clin Microbiol 2006; 
44(7):2518-2523.
141. Nobbenhuis MA, Helmerhorst TJ, van den Brule 
AJ, Rozendaal L, Jaspars LH, Voorhorst FJ et al. 
Primary screening for high risk HPV by home 
obtained cervicovaginal lavage is an alternative 
screening tool for unscreened women. J Clin 
Pathol 2002; 55(6):435-439.
142. Gok M, Heideman DA, van Kemenade FJ, 
Berkhof J, Rozendaal L, Spruyt JW et al. HPV 
testing on self collected cervicovaginal lavage 
specimens as screening method for women 
who do not attend cervical screening: cohort 
study. BMJ 2010; 340:c1040.
143. Virtanen A, Nieminen P, Luostarinen T, Anttila 
A. Self-sample HPV tests as an intervention for 
nonattendees of cervical cancer screening in 
Finland: a randomized trial. Cancer Epidemiol 
Biomarkers Prev 2011; 20(9):1960-1969.
144. Gok M, van Kemenade FJ, Heideman DA, Berkhof 
J, Rozendaal L, Spruyt JW et al. experience 
with high-risk human papillomavirus testing 
on vaginal brush-based self-samples of non-
attendees of the cervical screening program. Int 
J Cancer 2012; 130(5):1128-1135.
145. Huynh J, Howard M, Lytwyn A. Self-collection 
for vaginal human papillomavirus testing: 
systematic review of studies asking women 
their perceptions. J Low Genit Tract Dis 2010; 
14(4):356-362.
146. Khanna N, Mishra SI, Tian G, Tan MT, Arnold S, 
Lee C et al. Human papillomavirus detection in 
self-collected vaginal specimens and matched 
clinician-collected cervical specimens. Int J 
Gynecol Cancer 2007; 17(3):615-622.
147. Qiao YL, Sellors JW, eder PS, Bao YP, Lim JM, 
Zhao FH et al. A new HPV-DNA test for cervical-
cancer screening in developing regions: a 
cross-sectional study of clinical accuracy in rural 
China. Lancet Oncol 2008; 9(10):929-936.
148. Lazcano-Ponce e, Lorincz AT, Cruz-Valdez 
A, Salmeron J, Uribe P, Velasco-Mondragon 
e et al. Self-collection of vaginal specimens 
for human papillomavirus testing in cervical 
cancer prevention (MARCH): a community-
based randomised controlled trial. Lancet 2011; 
378(9806):1868-1873.
149. Ogilvie GS, Patrick DM, Schulzer M, Sellors JW, 
Petric M, Chambers K et al. Diagnostic accuracy 
of self collected vaginal specimens for human 
papillomavirus compared to clinician collected 
human papillomavirus specimens: a meta-
analysis. Sex Transm Infect 2005; 81(3):207-212.
150. Stewart De, Gagliardi A, Johnston M, Howlett R, 
Barata P, Lewis N et al. Self-collected samples for 
testing of oncogenic human papillomavirus: a 
systematic review. J Obstet Gynaecol Can 2007; 
29(10):817-828.
151. Belinson JL, Du H, Yang B, Wu R, Belinson Se, 
Qu X et al. Improved sensitivity of vaginal self-
collection and high-risk human papillomavirus 
testing. Int J Cancer 2012; 130(8):1855-1860.
152. Gravitt Pe, Belinson JL, Salmeron J, Shah KV. 
Looking ahead: a case for human papillomavirus 
testing of self-sampled vaginal specimens as a 
cervical cancer screening strategy. Int J Cancer 
2011; 129(3):517-527.
